- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01108861
GORE VIABAHN® Versus Plain Old Balloon Angioplasty (POBA) for Superficial Femoral Artery (SFA) In-Stent Restenosis (RELINE)
The GORE VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Versus Plain Old Balloon Angioplasty (POBA) for the Treatment of Superficial Femoral Artery (SFA) In-Stent Restenosis
This is a prospective, randomized, multi-center study recruiting patients with an in-stent restenosis in the superficial femoral artery. The safety and efficacity of the Viabahn endoprosthesis (W.L. Gore & Associates), a heparin-bonded endoprosthesis, is compared with plain old balloon angioplasty (POBA). In 4 Belgian and 2 German centers a total of 80 Patients will be recruited. Primary endpoint is primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) measuring a peak systolic velocity ratio ≤2.5, and without target lesion revascularization (TLR) within 12 months.
In comparison to POBA, it is expected that the use of the Viabahn endoprosthesis (W.L. Gore & Associates) will result in greater 12 month primary patency of treated superficial femoral artery in-stent restenotic lesions.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bonheiden, Belgium, 2820
- Imelda Hospital
-
Dendermonde, Belgium, 9200
- AZ Sint-Blasius
-
Edegem, Belgium, 2650
- Universitair Ziekenhuis Antwerpen
-
Genk, Belgium, 3600
- Zuid Oost Limburg
-
-
-
-
-
Bad Krozingen, Germany, 79189
- Herz-Zentrum Bad Krozingen
-
Leipzig, Germany, 04289
- Herzzentrum
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
General Inclusion Criteria:
- Patient presenting with lifestyle-limiting claudication, rest pain or minor tissue loss (Rutherford classification from 2 to 5)
- Patient is willing to comply with specified follow-up evaluations at the specified times
- Patient is >18 years old
- Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- Patient has a projected life-expectancy of at least 24 months
- Noninvasive lower extremity arterial studies (resting or exercise) demonstrate ankle-brachial index ≤0.8
- Patient is eligible for treatment with the Viabahn® Endoprosthesis (W.L. Gore)
- Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
Angiographic Inclusion Criteria
- Restenotic or reoccluded lesion located in a stent which was previously implanted (>30 days) in the superficial femoral artery, suitable for endovascular therapy
- Total target lesion length between 4 and 27 cm (comprising in-stent restenosis and adjacent stenotic disease)
- Minimum of 1.0cm of healthy vessel (non-stenotic) both proximal and distal to the treatment area
- Popliteal artery is patent at the intercondylar fossa of the femur to P3
- Target vessel diameter visually estimated to be >4mm and <7.6 mm at the proximal and distal treatment segments within the SFA
- Guidewire and delivery system successfully traversed lesion
- There is angiographic evidence of at least one-vessel-runoff to the foot, that does not require intervention (<50% stenotic)
Exclusion criteria :
- Untreated flow-limiting aortoiliac stenotic disease
- Presence of a chronic total occlusion, i.e. a complete occlusion of the failed bare stent that cannot be re-opened with thrombolysis or does not allow easy passage of the guidewire by the physician
- Any previous surgery in the target vessel
- Severe ipsilateral common/deep femoral disease requiring surgical reintervention
- Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment
- Femoral or popliteal aneurysm located at the target vessel
- Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
- No patent tibial arteries (>50% stenosis)
- Prior ipsilateral femoral artery bypass
- Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy
- Serum creatinine >2.5mg/dL within 45 days prior to study procedure unless the subject is currently on dialysis
- Major distal amputation (above the transmetatarsal) in the study or non-study limb
- Septicemia or bacteremia
- Any previously known coagulation disorder, including hypercoagulability
- Contraindication to anticoagulation or antiplatelet therapy
- Known allergies to stent or stent graft components (nickel-titanium or ePTFE)
- Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
- Patient with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
- Currently participating in another clinical research trial, unless approved by W.L. Gore & Associates in advance of study enrolment
- Angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment
- Any planned surgical intervention/procedure within 30 days of the study procedure
- Target lesion access not performed by transfemoral approach.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Endoprosthesis
GORE VIABAHN® Endoprosthesis
|
GORE VIABAHN® Endoprosthesis
|
Active Comparator: Plain old balloon angioplasty
|
Plain old balloon angioplasty
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on color-flow duplex ultrasound (CFDU) and without target lesion revascularization (TLR) within 12 months.
Time Frame: 1 year
|
1 year
|
Proportion of subjects who experience serious device-related adverse events within 30 days post-procedure
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30%.
Time Frame: during procedure
|
during procedure
|
|
Hemodynamic primary patency rate at 1, 6, 12, 24-month follow-up.
Time Frame: 1, 6, 12, 24-month follow-up
|
Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (systolic velocity ratio no greater than 2.5) and without prior TLR are defined as being primary patent at the given follow-up.
|
1, 6, 12, 24-month follow-up
|
Angiographic primary patency at 12 months
Time Frame: 1 year
|
Angiographic primary patency at 12 months, defined as no evidence of restenosis or occlusion within the originally treated lesion based on no Quantitative Angiographic evidence of stenosis > 50%
|
1 year
|
Primary assisted patency rate at 1, 6, 12, 24-month follow-up.
Time Frame: 1, 6, 12, 24-month follow-up
|
Primary assisted patency rate at 1, 6, 12, 24-month follow-up.
Defined as flow through the treated lesion maintained by repeat percutaneous intervention completed prior to complete vessel closure.
|
1, 6, 12, 24-month follow-up
|
Secondary patency rate at 1, 6, 12, 24-month follow-up
Time Frame: 1, 6, 12, 24-month follow-up
|
Secondary patency rate at 1, 6, 12, 24-month follow-up.
Defined as flow through the treated lesion maintained by repeat percutaneous intervention after occlusion of the target lesion.
|
1, 6, 12, 24-month follow-up
|
Target lesion revascularization (TLR)
Time Frame: entire follow-up
|
Target lesion revascularization (TLR) is defined as a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5 mm proximal and distal to the device/PTA edge
|
entire follow-up
|
Clinical success at follow-up
Time Frame: at 1 day and 1, 6, 12, 24-month follow-up
|
Clinical success at follow-up is defined as an improvement of Rutherford classification at 1 day and 1, 6, 12, 24-month follow-up of one class or more as compared to the pre-procedure Rutherford classification.
|
at 1 day and 1, 6, 12, 24-month follow-up
|
Serious adverse events
Time Frame: during entire follow-up
|
Serious adverse events as defined as any clinical event that is fatal, life-threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or unduly prolonged hospitalization, necessitates an intervention to prevent a permanent impairment of a body function or permanent damage to a body structure, is a congenital abnormality/birth defect, a fetal distress or fetal death, results in malignancy
|
during entire follow-up
|
Stent fracture rate at 12 months
Time Frame: 1 year
|
Stent fracture rate at 12 months, determined by using the following classifications on X-ray:
|
1 year
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMRP-100107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Disease
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
University of MichiganTerminatedPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
Clinical Trials on GORE VIABAHN® Endoprosthesis
-
W.L.Gore & AssociatesTerminatedPopliteal Artery AneurysmUnited States
-
W.L.Gore & AssociatesCompletedIatrogenic Vessel Injury
-
W.L.Gore & AssociatesCompletedPeripheral Arterial DiseaseJapan
-
W.L.Gore & AssociatesCompletedEvaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)Popliteal Artery AneurysmFrance
-
W.L.Gore & AssociatesRecruitingThoracic Aortic Aneurysm | Abdominal Aortic AneurysmSpain, Denmark, Italy, Norway, Netherlands, Sweden
-
W.L.Gore & AssociatesCompletedPeripheral Artery Disease | Vascular DiseaseUnited States, Germany, Italy, Sweden
-
W.L.Gore & AssociatesRecruitingTrauma Injury | Peripheral Artery Disease | Hemodialysis Access | Popliteal Aneurysm | Visceral Artery AneurysmsSpain, Italy, Germany, Sweden, Netherlands, United Kingdom, France, Belgium, Greece
-
W.L.Gore & AssociatesCompletedPeripheral Vascular DiseasesUnited States
-
Asociacion para el Estudio de la Enfermedades Vasculares...W.L.Gore & AssociatesUnknown
-
W.L.Gore & AssociatesActive, not recruitingPeripheral Vascular DiseasesGermany, Netherlands, France, Italy, Spain